Cargando…

Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advances

Immunosuppressive entities in the tumor microenvironment (TME) remain a major impediment to immunotherapeutic approaches for a majority of patients with cancer. While the immunosuppressive role of transforming growth factor-β (TGF-β) in the TME is well known, clinical studies to date with anti-TGF-β...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lind, Hanne, Gameiro, Sofia R, Jochems, Caroline, Donahue, Renee N., Strauss, Julius, Gulley, James L, Palena, Claudia, Schlom, Jeffrey
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7057416/ https://www.ncbi.nlm.nih.gov/pubmed/32079617 http://dx.doi.org/10.1136/jitc-2019-000433

Ejemplares similares

Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies
por: Strauss, Julius, et al.
Publicado: (2020)

A novel bifunctional anti-PD-L1/TGF-β Trap fusion protein (M7824) efficiently reverts mesenchymalization of human lung cancer cells
por: David, Justin M., et al.
Publicado: (2017)

Analyses of functions of an anti-PD-L1/TGFβR2 bispecific fusion protein (M7824)
por: Jochems, Caroline, et al.
Publicado: (2017)

Dual inhibition of TGF‐β and PD‐L1: a novel approach to cancer treatment
por: Gulley, James L., et al.
Publicado: (2022)

Simultaneous inhibition of CXCR1/2, TGF-β, and PD-L1 remodels the tumor and its microenvironment to drive antitumor immunity
por: Horn, Lucas A, et al.
Publicado: (2020)

Remodeling the tumor microenvironment via blockade of LAIR-1 and TGF-β signaling enables PD-L1–mediated tumor eradication
por: Horn, Lucas A., et al.
Publicado: (2022)

Dual PD-L1 and TGF-b blockade in patients with recurrent respiratory papillomatosis
por: Robbins, Yvette, et al.
Publicado: (2021)

M7824, a novel bifunctional anti-PD-L1/TGFβ Trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine
por: Knudson, Karin M., et al.
Publicado: (2018)

Bifunctional anti-PD-L1/TGF-βRII agent SHR-1701 in advanced solid tumors: a dose-escalation, dose-expansion, and clinical-expansion phase 1 trial
por: Liu, Dan, et al.
Publicado: (2022)

PD-1 and PD-L1 expression on PBMC subsets in normal individuals and cancer patients
por: Lepone, Lauren, et al.
Publicado: (2014)

Effect of age and cancer on peripheral immune cell subsets and their PD-1 and PD-L1 expression
por: Grenga, Italia, et al.
Publicado: (2015)

TGF-β: A novel predictor and target for anti-PD-1/PD-L1 therapy
por: Yi, Ming, et al.
Publicado: (2022)

Development of the Novel Bifunctional Fusion Protein BR102 That Simultaneously Targets PD-L1 and TGF-β for Anticancer Immunotherapy
por: Wu, Zhen-Hua, et al.
Publicado: (2022)

Selection of the Recommended Phase 2 Dose for Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF‐β and PD‐L1
por: Vugmeyster, Yulia, et al.
Publicado: (2020)

PAR1 Scaffolds TGFβRII to Downregulate TGF-β Signaling and Activate ESC Differentiation to Endothelial Cells
por: Gong, Haixia, et al.
Publicado: (2016)

Bintrafusp Alfa: A Bifunctional Fusion Protein Targeting PD-L1 and TGF-β, in Patients with Pretreated Colorectal Cancer: Results from a Phase I Trial
por: Spira, Alexander, et al.
Publicado: (2022)

Functional and mechanistic advantage of the use of a bifunctional anti-PD-L1/IL-15 superagonist
por: Knudson, Karin M, et al.
Publicado: (2020)

Co-targeting TGF-β and PD-L1 with radiation therapy: The Goldilocks principle
por: Bakhoum, Samuel F., et al.
Publicado: (2021)

Bispecific antibody targeting TGF-β and PD-L1 for synergistic cancer immunotherapy
por: Li, Tianye, et al.
Publicado: (2023)

Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody
por: Donahue, Renee N., et al.
Publicado: (2017)

Mutation of TGFβ-RII eliminates NSAID cancer chemoprevention
por: Martín-López, Juana, et al.
Publicado: (2017)

Enhanced neoepitope-specific immunity following neoadjuvant PD-L1 and TGF-β blockade in HPV-unrelated head and neck cancer
por: Redman, Jason M., et al.
Publicado: (2022)

Enhanced neoepitope-specific immunity following neoadjuvant PD-L1 and TGF-β blockade in HPV-unrelated head and neck cancer
por: Redman, Jason M., et al.
Publicado: (2023)

Hydroxysafflor Yellow A Suppresses MRC-5 Cell Activation Induced by TGF-β1 by Blocking TGF-β1 Binding to TβRII
por: Pan, Ruiyan, et al.
Publicado: (2017)

Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients with Non-Small Cell Lung Cancer Resistant or Refractory to Immune Checkpoint Inhibitors
por: Barlesi, Fabrice, et al.
Publicado: (2022)

TGFβ-dependent expression of PD-1 and PD-L1 controls CD8(+) T cell anergy in transplant tolerance
por: Baas, Marije, et al.
Publicado: (2016)

Model-informed approach for risk management of bleeding toxicities for bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1
por: Vugmeyster, Yulia, et al.
Publicado: (2022)

TGF-β attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
por: Mariathasan, Sanjeev, et al.
Publicado: (2018)

Observational Study of PD-L1, TGF-β, and Immune Cell Infiltrates in Hepatocellular Carcinoma
por: Ihling, Christian, et al.
Publicado: (2019)

Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort
por: Cho, Byoung Chul, et al.
Publicado: (2020)

Molecular characterization and expression of TGFβRI and TGFβRII and its association with litter size in Tibetan sheep
por: Zhang, Junxia, et al.
Publicado: (2023)

The miR-130a-3p/TGF-βRII Axis Participates in Inhibiting the Differentiation of Fibroblasts Induced by TGF-β1
por: Liu, Yanhong, et al.
Publicado: (2021)

Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies
por: Minnar, Christine M, et al.
Publicado: (2022)

Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients with Esophageal Adenocarcinoma: Results from a Phase 1 Cohort
por: Tan, Benjamin, et al.
Publicado: (2021)

Bullous pemphigoid secondary to bintrafusp alfa, a bifunctional fusion protein targeting TGF-beta and PD-L1
por: Wiggins, Claire J., et al.
Publicado: (2021)

Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with pretreated biliary tract cancer
por: Yoo, Changhoon, et al.
Publicado: (2020)

Case Report: Keratoacanthoma and type I diabetes secondary to treatment with PM8001, a bifunctional fusion protein targeting TGF-β and PD-L1
por: Qi, Rongbin, et al.
Publicado: (2023)

Selective inhibition of TGF-β1 produced by GARP-expressing Tregs overcomes resistance to PD-1/PD-L1 blockade in cancer
por: de Streel, Grégoire, et al.
Publicado: (2020)

Single-cell transcriptomics reveals the effect of PD-L1/TGF-β blockade on the tumor microenvironment
por: Lim, Yoong Wearn, et al.
Publicado: (2021)

Colocalized targeting of TGF-β and PD-L1 by bintrafusp alfa elicits distinct antitumor responses
por: Lan, Yan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ltr17qsohebbr0hk6ijt79bhoc